Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more
Dimerix Ltd (SBMJF) - Total Assets
Latest total assets as of June 2025: $91.18 Million USD
Based on the latest financial reports, Dimerix Ltd (SBMJF) holds total assets worth $91.18 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dimerix Ltd - Total Assets Trend (2021–2025)
This chart illustrates how Dimerix Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dimerix Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Dimerix Ltd's total assets of $91.18 Million consist of 79.2% current assets and 20.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Dimerix Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dimerix Ltd's current assets represent 79.2% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 74.9% of total assets in 2025, up from 55.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Dimerix Ltd Competitors by Total Assets
Key competitors of Dimerix Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Dimerix Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Dimerix Ltd generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Dimerix Ltd is currently not profitable relative to its asset base.
Dimerix Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.26 | 9.49 | 1.51 |
| Quick Ratio | 3.26 | 9.49 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $50.02 Million | $ 28.55 Million | $ 5.99 Million |
Dimerix Ltd - Advanced Valuation Insights
This section examines the relationship between Dimerix Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.04 |
| Latest Market Cap to Assets Ratio | 1.29 |
| Asset Growth Rate (YoY) | 184.2% |
| Total Assets | $91.18 Million |
| Market Capitalization | $117.63 Million USD |
Valuation Analysis
Above Book Valuation: The market values Dimerix Ltd's assets above their book value (1.29 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Dimerix Ltd's assets grew by 184.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dimerix Ltd (2021–2025)
The table below shows the annual total assets of Dimerix Ltd from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $91.18 Million | +184.23% |
| 2024-06-30 | $32.08 Million | +80.65% |
| 2023-06-30 | $17.76 Million | +7.64% |
| 2022-06-30 | $16.50 Million | +75.11% |
| 2021-06-30 | $9.42 Million | -- |